Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ying Cui, Guihua Shen, Linlin Ma & Qiubo Lv. (2021) Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer. Journal of Receptors and Signal Transduction 41:6, pages 546-552.
Read now
Read now
Khalid El Bairi, Mariam Amrani, Abdul Hafeez Kandhro & Said Afqir. (2017) Prediction of therapy response in ovarian cancer: Where are we now?. Critical Reviews in Clinical Laboratory Sciences 54:4, pages 233-266.
Read now
Read now
Articles from other publishers (16)
Laura E. Zweifler, Benjamin P. Sinder, Chris Stephan, Amy J. Koh, Justin Do, Emily Ulrich, Jobanpreet Grewal, Cecilia Woo, Lena Batoon, Kenneth Kozloff, Hernan Roca, Yuji Mishina & Laurie K. McCauley. (2024) Parathyroid hormone and trabectedin have differing effects on macrophages and stress fracture repair. Bone 179, pages 116983.
Crossref
Crossref
Chunxiu Lin, Peng Liu, Chaowen Shi, Lipeng Qiu, Dongsheng Shang, Ziwen Lu, Zhigang Tu & Hanqing Liu. (2022) Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. Fundamental & Clinical Pharmacology 37:2, pages 194-214.
Crossref
Crossref
Jiali Wang, Pengfei Wang, Zheng Zeng, Caiji Lin, Yiru Lin, Danli Cao, Wenqing Ma, Wenwen Xu, Qian Xiang, Lingjie Luo, Wenxue Wang, Yongwei Shi, Zixiang Gao, Yufan Zhao, Huidi Liu & Shu-Lin Liu. (2022) Trabectedin in Cancers: Mechanisms and Clinical Applications. Current Pharmaceutical Design 28:24, pages 1949-1965.
Crossref
Crossref
E. A. Bocharova, N. I. Kopytina & Е. Е. Slynko. (2021) Anti-tumour drugs of marine origin currently at various stages of clinical trials (review). Regulatory Mechanisms in Biosystems 12:2, pages 265-280.
Crossref
Crossref
Naike Casagrande, Cinzia Borghese, Andrea Favero, Cristina Vicenzetto & Donatella Aldinucci. (2021) Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma. Cancer Letters 500, pages 182-193.
Crossref
Crossref
Soumaya Souid, Dorra Aissaoui, Najet Srairi-Abid & Khadija Essafi-Benkhadir. (2020) Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response. Current Drug Targets 21:10, pages 996-1007.
Crossref
Crossref
Sudeep Gupta, Shona Nag, Shyam Aggarwal, Amit Rauthan & Narayanankutty Warrier. (2019) Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review. Journal of Ovarian Research 12:1.
Crossref
Crossref
Priyanka Banerjee, Ronghua Zhang, Cristina Ivan, Giovanni Galletti, Karen Clise-Dwyer, Federica Barbaglio, Lydia Scarfò, Miguel Aracil, Christian Klein, William Wierda, William Plunkett, Federico Caligaris-Cappio, Varsha Gandhi, Michael J. Keating & Maria Teresa S. Bertilaccio. (2019) Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunology Research 7:12, pages 2036-2051.
Crossref
Crossref
Er-Lan Yang, Bin Sun, Zi-Yi Huang, Jian-Guang Lin, Bo Jiao & Lan Xiang. (2019)
Synthesis, Purification, and Selective β
2
-AR Agonist and Bronchodilatory Effects of Catecholic Tetrahydroisoquinolines from
Portulaca oleracea
. Journal of Natural Products 82:11, pages 2986-2993.
Crossref
Crossref
Jamal Rahaman & Lorene M. Yoxtheimer. 2019. Ovarian Cancer-Challenges and Innovations. Ovarian Cancer-Challenges and Innovations
1
45
.
Alejandro Carazo, Přemysl Mladěnka & Petr Pávek. (2019) Marine Ligands of the Pregnane X Receptor (PXR): An Overview. Marine Drugs 17:10, pages 554.
Crossref
Crossref
Emanuela Tumini, Emilia Herrera-Moyano, Marta San Martín-Alonso, Sonia Barroso, Carlos M. Galmarini & Andrés Aguilera. (2019) The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability. Molecular Cancer Research 17:3, pages 773-782.
Crossref
Crossref
Khalid El Bairi, Atanas G. Atanasov, Mariam Amrani & Said Afqir. (2019) The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery. Biomedicine & Pharmacotherapy 109, pages 2492-2498.
Crossref
Crossref
Khalid El Bairi, Mariam Amrani & Said Afqir. (2018) Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Cancer Medicine 7:6, pages 2221-2246.
Crossref
Crossref
Meher Majety, Valeria Runza, Christian Lehmann, Sabine Hoves & Carola H. Ries. (2018) A drug development perspective on targeting tumor-associated myeloid cells. The FEBS Journal 285:4, pages 763-776.
Crossref
Crossref
Khalid El Bairi, Mounir Ouzir, Najda Agnieszka & Loubna Khalki. (2017) Anticancer potential of Trigonella foenum graecum: Cellular and molecular targets. Biomedicine & Pharmacotherapy 90, pages 479-491.
Crossref
Crossref